Inspire tumbles as TIGER-2 fails in cystic fibrosis
This article was originally published in Scrip
"Disappointing and unexpected" results from Inspire Pharmaceuticals' second Phase III trial of cystic fibrosis drug candidate denufosol tetrasodium sent the US firm's share tumbling by almost 60% to close at $3.47 on 3 January.
You may also be interested in...
The reasons behind Lilly's latest clinical failure had much less to do with the indication and more to do with repeating the past mistakes of Inspire and Sunesis. Unfortunately, that same die has already been cast for the trials of Biogen and Ophthotech that are due to report imminently.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.